Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT)
Sign Up to like & getrecommendations! Published in 2022 at "Pulmonary Circulation"
DOI: 10.1002/pul2.12083
Abstract: Abstract Even though pulmonary arterial hypertension (PAH) remains an incurable disease, the combination of PAH‐specific therapies allowed evolving from symptom‐based strategies to others aiming to move patients to low‐risk conditions. Endothelin‐1 (ET‐1) receptor antagonists emerged… read more here.
Keywords: arterial hypertension; macitentan; potent; pulmonary arterial ... See more keywords
Clinical use of macitentan in the treatment of connective tissue disease-associated pulmonary arterial hypertension
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Thoracic Disease"
DOI: 10.21037/jtd-24-151
Abstract: Background Connective tissue disease (CTD) is the second most common cause of the pulmonary arterial hypertension (PAH). Currently, clinical data concerning CTD-PAH is scarce. Our study aimed to assess the efficacy and safety of macitentan… read more here.
Keywords: ctd pah; disease; treatment; macitentan ... See more keywords
The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-word Prospective Study
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2021.811700
Abstract: Background: In a long-term event-driven trial, macitentan has demonstrated beneficial time to clinical worsening in patients with pulmonary arterial hypertension (PAH) and reduced PAH-related hospitalization rates compared with placebo. Macitentan is the most recently approved… read more here.
Keywords: macitentan; ambrisentan macitentan; pah patients; transition ... See more keywords
The biased apelin receptor agonist, MM07, reverses Sugen/hypoxia-induced pulmonary arterial hypertension as effectively as the endothelin antagonist macitentan
Sign Up to like & getrecommendations! Published in 2024 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2024.1369489
Abstract: Introduction: Pulmonary arterial hypertension (PAH) is characterised by endothelial dysfunction and pathological vascular remodelling, resulting in the occlusion of pulmonary arteries and arterioles, right ventricular hypertrophy, and eventually fatal heart failure. Targeting the apelin receptor… read more here.
Keywords: receptor; macitentan; right ventricular; apelin receptor ... See more keywords